Dr. Adi Zuloff-Shani reports

CLEARMIND MEDICINE SUBMITS THREE ADDITIONAL INTERNATIONAL PATENT APPLICATIONS FOR INNOVATIVE MDMA, IBOGAINE AND KETAMINE COMPOUNDS

Clearmind Medicine Inc. has submitted three additional patent applications under the international Patent Cooperation Treaty (PCT) as part of its continuing collaboration with SciSparc Ltd., a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

The patent applications refer to novel proprietary compositions of MDMA, ibogaine and ketamine, each with palmitoylethanolamide (PEA), the active ingredient of SciSparc's proprietary CannAmide. These applications were previously filed as provisional patent applications with the United States Patent and Trademark Office (USPTO). Over all, as part of this collaboration, eight other patent applications have been filed by Clearmind with the USPTO for various combinations, three of them for the combination of SciSparc's PEA with Clearmind's MEAI compound (5-methoxy-2-aminoindane) for the treatment of alcohol use disorder, treatment of cocaine addiction and treatment of obesity and its related metabolic disorders. In addition, seven patent applications were filed under the international PCT.

Dr. Adi Zuloff-Shani, Clearmind's chief executive officer, stated: "These latest patent applications are expected to significantly expand our IP [intellectual property] protection and further enhance our leadership in the psychedelic space. Over all, we now have 27 granted patents and 24 pending patent applications across 15 patent families, nine of which have been granted in major jurisdictions such as the U.S., Europe, China and India. In parallel, we are moving forward aggressively on our clinical programs and look forward to providing further updates on our progress."

About Clearmind Medicine Inc.

Clearmind is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods or supplements.

We seek Safe Harbor.